HIGHLIGHTS
- who: Shaohong Dong from the Federation, Russia University of Padua, Italy have published the article: Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: A pilot study on Chinese patients, in the Journal: (JOURNAL)
- what: Evolocumab altered inflammatory status in patients with ACS in the early period Given the rapid and evident effect of evolocumab in lipid burden reduction, and previous hypothesis on the This study is one of the first studies focusing on immediate lipid-lowering efficacy and systematic inflammatory pattern changes mediated by the in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.